MAYER B. DAVIDSON, M.D.
`CURRICULUM VITAE
`
`PERSONAL INFORMATION
`
`Business Address:
`
`Business Phone:
`FAX
`E-mail
`
`Home Address:
`
`Date of Birth:
`
`Place of Birth:
`
`Citizenship:
`
`Marital Status:
`
`Department of Internal Medicine
`Charles Drew University
`1731 East 120th Street
`Los Angeles, CA 90059
`
`(323) 357-3439
`(323) 563-4887
`mayerdavidson@cdrewu.edu
`
`3616 Ocean View Avenue
`Los Angeles, CA 90066
`(310) 636-1436 (Phone)
`(310) 632-5236 (FAX)
`
`April 11, 1935
`
`Baltimore, MD
`
`United States Citizen
`
`Married to Roseann Herman
`
`Social Security Number:
`
`Last four digits-3791
`
`EDUCATION
`
`Undergraduate:
`
`Medical:
`
`Internship:
`(Internal Medicine)
`
`1957
`
`1961
`
`1961-1962
`
`Swarthmore College
`Swarthmore, PA
`Major: Chemistry
`Degree: A.B.
`
`Harvard Medical School
`Boston, MA
`Degree: M.D.
`
`Cornell Medical Service
`Bellevue Hospital
`New York, New York
`
`- 1 -
`
`Mylan EX 1007, Page 1
`
`

`
`Residency:
`(Internal Medicine)
`
`Research Fellowship:
`
`Cornell Medical Service
`Bellevue Hospital
`New York, New York
`
`University of Washington
`Affiliated Hospitals
`Seattle, Washington
`
`University of Washington
`King County Hospital
`Seattle, Washington
`Endocrinology and Metabolism
`
`1962-1963
`
`1963-1964
`
`1964-1966
`
`LICENSURE:
`
`California State Certificate Number G18264
`
`BOARD CERTIFICATIONS
`
`PROFESSIONAL EXPERIENCE
`
`Diplomate: American Board of
`Internal Medicine (#27505)
`
`Diplomate: American Board of
`Internal Medicine, Endocrinology
`and Metabolism Subspecialty Boards
`
`1969
`
`1972
`
`2004-2009
`Principal Investigator
`Clinical Center for Research Excellence
`Charles R. Drew University
`
`Director, Clinical Trials Unit
`Charles R. Drew University
`
`Professor of Medicine
`Charles R. Drew University
`
`1998-2004
`
`1998-present
`
`Associate Director,
`Clinical Diabetes
`City of Hope National Medical Center
`
`1995-1998
`
`Sabbatical in molecular biology laboratory 1990
`of Aldons J. Lusis, Ph.D.
`UCLA School of Medicine
`
`Director, Diabetes Program
`Cedars-Sinai Medical Center
`
`1979-1995
`
`- 2 -
`
`Mylan EX 1007, Page 2
`
`

`
`Professor of Medicine
`UCLA School of Medicine
`
`1978-present
`
`Associate Professor of Medicine
`UCLA School of Medicine
`
`1974-1978
`
`Assistant Professor of Medicine
`UCLA School of Medicine
`
`Clinical Assistant,
`Harvard Medical School
`
`1969-1974
`
`1968-1969
`
`1966-1969
`Research Internist, United States
`Army Institute of Environmental Medicine
`Natick, Massachusetts
`
`Attending Physician,
`Diabetic Clinic
`Boston City Hospital
`
`1966-1968
`
`PROFESSIONAL ACTIVITIES
`
`1978-1981
`1980-1981
`1980-1983
`
`Editorships, Editorial Boards and Advisory Committees:
` American Diabetes Association, Research Committee
` Advisory Committee, California Diabetes Program
` Editorial Board, The Diabetes Educator (official journal of the
` American Association of Diabetes Educators)
` Editorial Board, Journal of Clinical Endocrinology & Metabolism 1981-1984
`1993-1995
`1985-1987
`1986-2002
`1987-1989
`1987-1988
`1989-1992
`1990-1992
`1992-2014
`1993-1994
`1993-2000
`1998-2001
`2000-2002
`2001-2006
`2002-2006
`2003-2010
`
` Editorial Board, Diabetes Care
` Editorial Board, Geriatrics
` Editorial Board, Diabetes Reports
` Editorial Board, Today in Medicine
` Editorial Board, Clinical Diabetes
` Editorial Board, Diabetes Spectrum
` Editorial Board, Diabetes Research and Clinical Practice
` Editorial Board, Women's Health News
` Editorial Board, The Health Information Network
` Consulting Editor, Hippocrates
` Founding Editor, Current Diabetes Reports
` Associate Editor, Endo Trends
` Editor-in-Chief, Diabetes Care
` Data Safety Monitoring Board (Chair), City of Hope National
`Medical Center
` Data Safety Monitoring Board, Metabolex, Inc
`
`2004-2007
`
`- 3 -
`
`Mylan EX 1007, Page 3
`
`

`
` Co-Editor-in-Chief, Clinical Insights into Diabetes
` Editorial Board, International Diabetes
`
`2005-2008
`2009-present
`
`Professional Associations:
` Boylston Medical Society (local medical school society)
` American Diabetes Association
` American Federation for Clinical Research
` Western Society for Clinical Research
` The Endocrine Society
` Sigma Xi
` American Society for Clinical Investigation
` Western Association of Physicians
` American Association of Diabetes Educators
` American Association for the Advancement of Science
`
`Consulting:
` National Advisor--The Diabetes Center - Humana Hospital,
` Phoenix, Arizona
` Consultant, American Medical Association, Dept of Drugs
` Consultant, Health Net, Woodland Hills, CA
` Consultant, Inhale Therapeutics, Palo Alto, CA
` Consultant, Masimo Corporation
` Consultant, Access-to-Care for the Elderly Project
`sponsored by Rand/Physicians Review Commission
` Consultant, Alza Pharmaceuticals
` Consultant, Parke-Davis
` Consultant, Bristol-Myers Squibb
` Consultant, Baxter Health Care Corporation
` Consultant, U.S. Pharmaceuticals Group; Pfizer, Inc
` Consultant, Bayer Corporation, Pharmaceutical Division
` Consultant, Federal Trade Commission
` Consultant, Biostores International, Inc
` Consultant, Institute for Healthcare Quality
` Consultant, Prudential Healthcare
` Consultant, Health Desk Corporation, Inc
` Consultant, Amylin Pharmaceuticals
` Consultant, Hoechst Marion Roussel, Inc
` Consultant, Medaction
` Consultant, Health International
` Consultant, Calyx Therapeutics, Inc
` Consultant, Pace Healthcare Management, L.P.
` Consultant, Asta Medical, Inc
` Consultant, Aerogen
` Consultant, SmithKline Beecham Pharmaceuticals
` Consultant, Medisense, Inc.
`
`- 4 -
`
`1985-1992
`1985,1989,1991,1993
`1993, 1994
`1993, 1994
`1993
`
`1994,1995
`1994
`1994
`1994
`1995-1996
`1995
`1995
`1995
`1995-1997
`1996
`1996-1998
`1996-1998
`1996
`1997
`1997-1998
`1997-2005
`1997-2003
`1998
`1998
`1998-2005
`1998
`1998, 2002
`
`Mylan EX 1007, Page 4
`
`

`
` Consultant, Purdue Pharma, L.P.
` Consultant, LifeChart.Com
` Consultant, Ontogene Corporation
` Consultant, Sanofi-Aventis
`
` Consultant, Bexel
` Consultant, Isotechnika
` Consultant, Amgen
` Consultant, Daiichi Sankyo
` Consultant, Merck & Co., Inc
` Diabetes Prevention & Management Workgroup, Department
`of Health Services, Sate of California
` Consultant, MannKind Corporation
` Consultant, Calibra, Inc (nee Seattle Medical Technologies, Inc)
` Consultant, Novo Nordisk
` Consultant, Diabetech LP
` Consultant, XOMA (US) LLC
` Consultant, Metabolex, Inc
` Consultant, Discovery Institute of Medical Education
` Consultant, Healthy Interactions, Inc
`
`HONORS AND AWARDS
`
`USPHS Research Fellowship, NIAMD
`Second Prize Research Contest, American Diabetes Association
`First Prize Research Contest, American Diabetes Association
`Veterans Administration, Clinical Investigator
`American Diabetes Association, Research and Development Award
`Fellow, American College of Physicians
`Upjohn Award for the Outstanding Physician Educator in the Field
`of Diabetes by the American Diabetes Association
`Robert H Williams/Rachmiel Levine Award-Western Metabolism Club
`The Banting Medal of the American Diabetes Association for
`Distinguished Service
`Arabella Carter Award in Recognition of Outstanding Social Service
`by Swarthmore College
`Bank of America, Local Hero Award
`Outstanding Professor Award, Charles Drew University
`Jefferson Award for Public Service by the Jacqueline Kennedy-Onassis
`Award Organization
`Mahal Access to Health Care and Disparities Award by the California
`Medical Association Foundation
`Outstanding Volunteer Award by the Association for Fundraising
`Professionals of Greater Los Angeles
`Visionary Award by the Venice Family Clinic for co-founding the
`clinic and continual volunteering for 40 years
`
`- 5 -
`
`1999
`2000
`2000
`2000, 2003-2005,
`2009, 2010, 2011
`2003-2005
`2004-2006
`2006, 2012
`2006
`2007
`
`2007-2008
`2007
`2007-2008
`2007
`2007-present
`2008
`2008
`2009-present
`2009-present
`
`1965-1966
`1965
`1966
`1969-1972
`1974-1975
`1982
`
`1990
`1995
`
`1998
`
`2007
`2007
`2009
`
`2010
`
`2010
`2010
`
`2011
`
`Mylan EX 1007, Page 5
`
`

`
`Mentor of the Year Award, Charles R. Drew University
`Outstanding Physician-Clinician in Diabetes Award, American Diabetes
`Association
`
`2012
`2016
`
`COMMUNITY SERVICE
`
`Co-Founder, Member of the Board of Directors & Volunteer
`Venice Family Clinic (largest free medical clinic in the U.S.)
`Board of Directors, American Diabetes Association of
`Southern California
`President, American Diabetes Association of Southern CA
`Co-founder, Los Angeles Chapter, American Diabetes
`Association, California Affiliate
`Board of Directors, American Diabetes Association (National)
`
`Vice President, American Diabetes Association (National)
`President-Elect, American Diabetes Association (National)
`President, American Diabetes Association (National)
`
`1970-present
`
`1975-1986
`
`1978-1979
`1986
`
`1986-1989
`1994-1999
`1995-1996
`1996-1997
`1997-1998
`
`CLINICAL AND PHARMACEUTICAL COMPANY RESEARCH GRANTS:
`
`February, 2004
`
`A Phase 3, Randomized, Double-Blind, Active Controlled,
`Multicenter Trial to Evaluate the Safety and Efficacy of BMS-
`298585 in Combination with Metformin Compared to Pioglitazone
`in Combination with Metformin in Subjects with Type 2 Diabetes
`Who Have Inadequate Glycemic Control on Metformin Therapy
`Alone (Protocol: CV168025)
`Sponsor: Bristol-Myers Squibb
`Amount: $8,570 per patient
`Sub-Investigator
`
`A Randomized, Double-Blind, Placebo-Controlled, 4-Week
`Study to Evaluate the Safety and Efficacy of T0903131 Besylate
`in Subjects with Type 2 Diabetes Mellitus (Protocol #: T-131-004)
`Sponsor: Tularik
`Amount: $5,340 per patient
`Principal Investigator
`
`January, 2004
`
`A Multicenter, Double-Blind, Randomized, Placebo- and
`Active-Controlled Dose-Range Finding Study of L-000224715
`in Patients With Type 2 Diabetes Mellitus Who Have Inadequate
`Glycemic Control (Protocol: 010)
`Sponsor: Merck
`Amount: $2,459 per patient
`Principal Investigator
`
`February, 2003
`
`- 6 -
`
`Mylan EX 1007, Page 6
`
`

`
`A Multicenter, Randomized, Double-Blind, Parallel-Group,
`Placebo-Control, Clinical Evaluation of Insulin Plus Rosglitazone
`(2 mg and 4mg) Compared to Insulin Plus Placebo for 24 weeks
`in Subjects with Type 2 Diabetes Mellitus Who Are Inadequately
`Controlled On Insulin AVANDIA 347
`Sponsor:Glaxo-SmithKline
`Amount: $3,600 per patient
`Principal Investigator
`
`January, 2003
`
`The Effect of Self Monitoring of Blood Glucose in
`Diabetic Patients NOT Taking Insulin
`Sponsor: Eli Lilly & Company
`Amount: $36,000
`Principal Investigator
`
`A Multinational, Randomized, Double-Blind Placebo-
`Controlled, Forced-Titration, 2x2 Factorial Design Study
`of the Efficacy and Safety of Long Term Administration
`of Nateglinide and Valsarten in the Prevention of Diabetes
`and Cardiovascular Outcomes in Subjects with Impaired
`Glucose Tolerance (IGT) (NAVIGATOR)
`Sponsor: Novartis
`Amount: $5,935 per patient
`Principal Investigator
`
`Improving Diabetes Management in Older Patients
`Admitted to a Hospital for a Cardiac Event
`Sponsor: American Diabetes Association
`Amount: $375,000
`Principal Investigator
`
`Effect of Patient Reminder Cards at an Office Visit on
`Process Measures of Diabetes Care
`Sponsor: American Diabetes Association
`Amount: $300,000
`Principal Investigator
`
`Multicenter, Randomized, Double-Blind, Active
`Controlled Trial to Compare the Efficacy and Safety of
`104 Weeks of Starlix (Nateglinide) Plus Metformin vs.
`Glyburide plus Metformin in Drug Naïve Subjects with
`Type 2 Diabetes Mellitus Who Have Inadequate Glycemic
`Control with Diet and Exercise (STARLIX/PRESERVE)
`Sponsor: Novartis
`Amount: $9,330 per patient
`
`- 7 -
`
`July, 2002
`
`February, 2002
`
`July, 2001
`
`March, 2001
`
`October, 2001
`
`Mylan EX 1007, Page 7
`
`

`
`Principal Investigator
`
`Randomized, Double-Blind Study to Compare the
`Durability of Glucose Lowering and Preservation of
`Pancreatic Bveta-Cell Function of Rosiglitazone Mono-
`Therapy Compared to Metformin or Glyburide/
`Glibenclamide in Patients with Drug-Naïve, Recently
`Diagnosed Type 2 Diabetes (3 Years) (ADOPT)
`Sponsor: GlaxoSmithKline
`Amount: $11,675 per patient
`Principal Investigator
`Randomized, Multicenter, Double-Blind, Active
`Controlled Study with Two Parallel Groups Comparing
`the Minimum Post Clamp Blood Glucose in Type 2
`Diabetics Given Nateglinide or Glyburide 90 Minutes
`Prior to the Discontinuation of a Hyperglycemic Clamp
`Sponsor: Novartis
`Amount: $4,531 per patient
`Principal Investigator
`
`Managed Care in Minority Populations
`Sponsor: American Diabetes Association
`Amount: $300,000
`Principal Investigator
`
`The Effect of PNU-182716 on Hb A1C Levels in Type 2
`Diabetic Patients, A Double-Blind, Placebo-Controlled,
`Randomized Multicenter Dose Finding and Dose
`Frequency Study
`Sponsor: Pharmacia & Upjohn
`Amount: $8,800 per patient
`Principal Investigator
`
`Target Glycemic Control and the Incidence of Symptomatic
`Nocturnal Hypoglycemia in Insulin Naïve Subjects
`with type 2 Diabetes on Oral Hypoglycemic Agents
`and Treated with Insulin Glargine or NPH Human Insulin
`Sponsor: Aventis
`Amount: $4,800 per patient
`Principal Investigator
`
`A Double-Blind, Placebo-Controlled, Randomized
`Study of the Safety and Efficacy of a Combination of
`Metformin and 30 Mg or 45 Mg of Pioglitazone in the
`Treatment of Patients with Type 2 (Non-Insulin
`Dependent) Diabetes Mellitus
`
`- 8 -
`
`February, 2001
`
`August, 2001
`
`July, 2000
`
`March, 2000
`
`January, 2000
`
`January, 2000
`
`Mylan EX 1007, Page 8
`
`

`
`Sponsor: Takeda America
`Amount: $3,940 per patient
`Principal Investigator
`A 20 Week, Double-Blind, Randomized, Active-
`Controlled, Multicenter Study Comparing Efficacy and
`Safety of Troglitazone Plus Metformin or Rosiglitazone
`Plus Metformin to Placebo Plus Metformin in Type 2
`Diabetic Patients Not Optimally Controlled on Metformin
`Sponsor: Parke-Davis
`Amount:$2,520 per patient
`Principal Investigator
`
`Long Term Safety of Inhaled Human Insulin: Extension
`of Therapy in Subjects with Type 1 or Type 2 Diabetes
`Mellitus Completing Phase III Randomized Treatment Trials
`Sponsor: Pfizer
`Amount:$3,558 per patient
`Principal Investigator
`
`Effect of Pancreas Tonic on Hemoglobin A1C Levels
`In Type 2 Diabetic Patients Treated with Diet Alone
`or Oral Antidiabetes Drugs
`Sponsor: U. S. Botanicals
`Amount: $4,090 per patient
`Principal Investigator
`
`Efficacy and Safety of Inhaled Human Insulin Therapy
`Compared with Subcutaneous Human Insulin Therapy
`in Subjects with Type 2 Diabetes Mellitus: A Six-month,
`Outpatient, Parallel Comparative Trial
`Sponsor: Pfizer
`Amount: $5,941 per patient
`Principal Investigator
`
`Efficacy and Safety of Inhaled Human Insulin Therapy
`in Subjects with Type 2 Diabetes Mellitus Not Well
`Controlled with Combination Oral Agents: A Three-
`Month, Outpatient, Parallel Comparative Trial
`Sponsor: Pfizer
`Amount: $5,375 per patient
`Principal Investigator
`
`Efficacy and Safety of Inhaled Human Insulin Therapy
`in Subjects with Type 2 Diabetes Mellitus Not Optimally
`Controlled with Diet and Exercise: A Three-Month,
`Outpatient, Parallel Comparative Trial
`Sponsor: Pfizer
`Amount: $4,759 per patient
`
`- 9 -
`
`November, 1999
`
`January, 2000
`
`October, 1999
`
`February, 1999
`
`February, 1999
`
`February, 1999
`
`Mylan EX 1007, Page 9
`
`

`
`Principal Investigator
`
`A Double-Blind, Randomized, Placebo-Controlled,
`Multicenter, Two-Year Study of the Effect of the
`Anti-Glycation Agent, Exo-226, on Renal Dysfunction
`in Two Strata of Albuminuric Diabetic Patients
`Sponsor: Exocell, Inc.
`Amount: $4,400 per patient
`Principal Investigator
`
`A Multicenter, Randomized, Double-Blind, Placebo-
`Controlled, Parallel Study of the Efficacy and Safety
`of Metformin Hydrochloride for the Treatment of
`Pediatric Subjects with Type 2 Diabetes Mellitus
`Sponsor: Bristol-Myers Squibb
`Amount: $5,550 per patient
`Principal Investigator
`
`A Double-Blind, Placebo-Controlled, Multicenter, Phase
`III Study to Evaluate the Effects of Pramlinitide (AC137)
`on Glycemic Control as Determined by Glycated Hemoglobin
`in Patients with Type 1 Diabetes Mellitus
`Sponsor: Amylin Pharmaceuticals
`Amount: $37,189
`Principal Investigator
`
`A Randmized Double-Blind, Placebo-Controlled
`Multicenter Study Measuring the Effects of CI-991 with
`or without Insulin on Reaching a Treatment Target in
`Noninsulin Dependent Diabetes Mellitus (NIDDM) in
`Patients Requiring Insulin
`Sponsor: Parke-Davis Medical Research
`Amount: $21,000
`Principal Investigator
`
`Dose-Response Study of Various Dose Levels of
`Metformin Compared to Placebo in Patients with NIDDM
`Sponsor: Bristol-Myers Squibb
`Amount: $45,000
`Co-Investigator
`
`Randomized, Double-Blind, Placebo-Controlled Multicenter
`Study of the Effect of CI-991 on Glycemic Control in Insulin
`Treated NIDDM
`Sponsor: Sankyo Pharmaceuticals
`Amount: $65,580
`Co-Principal Investigator
`
`- 10 -
`
`August, 1999
`
`June, 1999
`
`January, 1998
`
`February, 1997
`
`June, 1995
`
`March, 1995
`
`Mylan EX 1007, Page 10
`
`

`
`A 6-month Study of CI-991 in Patients with NIDDM
`Sponsor: Warner-Lambert Company
`Amount $50,000
`Co-Principal Investigator
`
`NIDDM Family Acquisition Center
`Sponsor: American Diabetes Association
`Amount: $244,782
`Co-Investigator
`
`Effect of Hydrolyzed Guar on Glycemic Response in Patients
`with IDDM
`Sponsor: Sandoz Nutrition
`Amount: $36,311
`Principal Investigator
`
`Effect of CI-991 in Treating NIDDM Patients
`Sponsor: Warner Lambert Company
`Amount: $121,890
`Co-principal Investigator
`
`The Safety and Effectiveness of the Combination of
`Metformin Plus Glyburide in Patients with NIDDM
`Sponsor: Lipha Pharmaceuticals
`Amount: $78,480
`Co-principal Investigator
`
`March, 1995
`
`July, 1993
`
`February, 1993
`
`April, 1992
`
`September,1989
`
`Effect of Metformin on Glyburide-Treated Diabetic Patients
`Sponsor: Lipha Pharmaceuticals
`Amount $85,715
`Principal Investigator
`
`April, 1988
`
`- 11 -
`
`Mylan EX 1007, Page 11
`
`

`
`INVITED LECTURES - ACADEMIC OR NATIONAL/INTERNATIONAL AUDIENCE
`
`"Workshop on fat cell metabolism in obesity." Brown University, Providence, RI, May, 1976.
`
`"Does control make a difference?" New Mexico Metabolism Symposium, Taos, NM, March,
`1980.
`
`"Impaired carbohydrate tolerance in the elderly." Western Gerontological Society Meeting,
`San Diego, CA, March, 1982.
`
`Visiting Professor, The Brooklyn Hospital, Downstate Medical Center, State University of New
`York. Brooklyn, NY, June, 1982.
`
`Visiting Professor Tri-service General Hospital, National Defense Medical Center.” Taipei,
`Taiwan, Republic of China, November, 1982.
`
`"Control and complications--an update." Postgraduate Course sponsored by the American
`Diabetes Association, Denver, CO, January, 1983.
`
`"The pathogenesis of type 2 diabetes mellitus: insulin secretion defects versus insulin antagonism
`(receptor and/or post-receptor defects)." Western Metabolism Club, Carmel, CA, February, 1983.
`
`"Modern concepts about insulin secretion and action." Postgraduate course sponsored by the
`American Diabetes Association, Los Angeles, CA, January, 1984.
`
`Visiting Professor, Fitzsimmons Army Hospital. University of Colorado School of Medicine,
`Denver, CO, September, 1984.
`
`"Effect of growth hormone on carbohydrate and lipid metabolism." Acromegaly Centennial
`Symposium, San Francisco, CA, July, 1986.
`
`"Insulin resistance." Workshop at the Endocrine Society Postgraduate Assembly, Los Angeles,
`CA, November, 1986.
`
`"Direct effects of a sulfonylurea agent (glyburide) on glycogen metabolism in cultured
`hepatocytes." Second Southern California Diabetes Research Symposium, Long Beach, CA,
`December, 1986.
`
`"In search of the mechanism of growth hormone-induced insulin antagonism." Research
`Seminar, Beckman Research Institute, Duarte, CA, January, 1988.
`
`"Etiologic and pathogenetic mechanisms in type 2 diabetes". New Mexico Metabolism
`Symposium, sponsored by Lovelace Medical Foundation, American Diabetes Association, New
`Mexico Affiliate and New Mexico Chapter. American College of Physicians, Taos, New Mexico,
`March, 1988.
`
`- 12 -
`
`Mylan EX 1007, Page 12
`
`

`
`Visiting lecturer sponsored by the Chinese Diabetes Association and the National Defense
`Medical Center. Taipei, Taiwan, ROC, March, 1988.
`
`"New insights into the pathogenesis of type 2 diabetes mellitus." American College of Physicians
`Postgraduate Course, San Francisco, CA, October, 1988.
`
`"Intracellular mechanism of action of sulfonylurea agents." University of Southern California
`School of Medicine, Los Angeles, CA, May, 1989.
`
`"Pathophysiology and management of type 2 diabetes, l989." 41st Postgraduate Assembly of the
`Endocrine Society, New Orleans, Louisiana, October, 1989.
`
`"Diabetes mellitus." Intensive Course in Geriatric Medicine and Board Review, Postgraduate
`Course sponsored by the American College of Physicians, Los Angeles, CA, January, 1990.
`
`"Sulfonylureas, ion channel and muscle glucose transport." New Mexico Metabolism
`Symposium, Taos, New Mexico, March, 1991.
`
`"Enteral nutrition in patients with impaired glucose tolerance or diabetes." VIII Congress of the
`Spanish Society of Parenteral and Enteral Nutrition, Santender, Spain, June, 1991.
`
`"Management of the acute complications of diabetes mellitus." 14th International Diabetes
`Federation Congress, Washington, DC, June, 1991.
`
`"Unravelling the cause of diabetes mellitus." Selected Topics in Diabetes Mellitus. National
`Symposium sponsored by UCLA Multicampus Division of Family Medicine, Los Angeles, CA,
`June, 1992.
`
`Visiting Professor, Wright State University. "Achieving diabetic control: reality or fantasy?"
`"Update on the pathogenesis of type 2 diabetes." "Diabetic complications, why and what can be
`done." Dayton, Ohio, October, 1992.
`
`"Metformin, phenformin's (DBI) cousin." 40th American Diabetes Association Postgraduate
`Course, San Francisco, CA, January, 1993.
`
`"Diagnosis, genetics and etiology of type 1 and type 2 diabetes mellitus." "Treatment of the
`patient with diabetes mellitus." "Management of the microvascular complications of diabetes
`mellitus (retinopathy, nephropathy and neuropathy)." "Prevention and management of the
`macrovascular complications of diabetes mellitus (hypertension and blood lipids)." Update and
`Current Treatments in Clinical Medicine. Symposium sponsored by the University of California,
`Irvine and Memorial/UCI Center for Health Education Island of Hawaii, October, 1993.
`
`"Diabetes conundrums for the nonplussed physician." The Endocrine Society's 45th Postgraduate
`Assembly, San Francisco, California, November, 1993.
`
`- 13 -
`
`Mylan EX 1007, Page 13
`
`

`
`"Can type II diabetes be treated effectively?" 21st Annual Kilo Diabetes Symposium - Current
`Topics in Diabetes and Vascular Disease, St. Louis, Missouri, November, 1993.
`"Screening for and diagnosing diabetes mellitus." Council on Epidemiology and Statistics,
`National Meeting of the American Diabetes Association, New Orleans, LA, June, 1994.
`
`"Hypertension in diabetics." National Meeting of the Endocrine Society, Anaheim, CA, June,
`1994.
`
`"Diabetes mellitus." California Internal Medicine Board Review Course. Sponsored by the
`American College of Physicians and UCLA Department of Medicine, Los Angeles, CA, July,
`1994.
`
`"Nurse clinician management of diabetes in managed care." Disease State Management: Diabetes
`as a Model for Managed Care. Symposium sponsored by the Juvenile Diabetes Foundation and
`Becton Dickinson & Co., Franklin Lakes, NJ, September, 1994.
`
`"Oral hypoglycemia therapy: are the newer agents better?" Cardiovascular Disease and Diabetes:
`Therapeutic Dilemmas. Symposium sponsored by the American College of Osteopathic Family
`Physicians, San Francisco, CA, November, 1994.
`
`"Should people be screened for diabetes? If so, will it alter the outcome?" 42nd American
`Diabetes Association Postgraduate Course, San Diego, CA, January, 1995.
`
`"Diabetes mellitus." Family Practice Board Review Course. Sponsored by the Urbana Institute,
`Los Angeles, CA, May, 1995.
`
`"Diabetes mellitus." Internal Medicine Board Review Course. Sponsored by the Urbana
`Institute, Los Angeles, CA, June, 1995.
`
`"Can intensive diabetes management occur successfully in the HMO setting?" Providing care for
`patients in a changing health care environment. Symposium at National Meeting of the American
`Diabetes Association. Atlanta, GA, June, 1995.
`
`"Glycemic control and the microvascular and neuropathic complications of NIDDM." Consensus
`Development Conference on the Pharmacologic Treatment of Hyperglycemia in NIDDM.
`Symposium of the American Diabetes Association. Philadelphia, PA, July, 1995.
`
`"Diabetes mellitus." California Internal Medicine Board Review Course. Sponsored by the
`American College of Physicians and UCLA Department of Medicine, Los Angeles, CA, July,
`1995.
`
`"Why the DCCT should apply to NIDDM." A System of Intensive Diabetes Self Management:
`How to Reduce the Complication Rate of NIDDM and IDDM and Prove It. Symposium
`sponsored by the American Association of Clinical Endocrinologists, Keystone, CO, February,
`1996.
`
`"Management of diabetes under managed care." California Society of Internal Medicine, Kauai,
`Hawaii, July, 1996.
`
`- 14 -
`
`Mylan EX 1007, Page 14
`
`

`
`"Crafting a diabetes disease management program for managed care." The Disease Management
`Congress, Seattle, WA. July, 1996.
`
`"Who will be the diabetes caregiver of the future: specialists or primary care physicians and
`support staff?" The Disease Management Congress, Washington, DC, September, 1996.
`
`"Diabetes care under managed care." The Disease Management Congress, San Francisco, CA,
`January, 1997.
`
`"New strategies for managing diabetes care under managed care." Diabetes Outcomes & Disease
`Management. Dallas, TX, March, 1997.
`
`"Diabetes care under managed care." New Developments in the Clinical Management of Type II
`Diabetes: Focus on the Role of Insulin Sensitizers. Symposium sponsored by The Institute for
`Medical Studies, Phoenix, Az, May, 1997.
`
`"The treatment of diabetes mellitus: promise versus reality." Advances in the Management of
`Diabetic Complications & Novel Therapeutic Development, Symposium sponsored by The
`Royal Society, London, England, April, 1998.
`
`“A new paradigm for diabetes care.” Endocrine Grand Rounds, Brigham and Women’s Hospital,
`Harvard Medical School, Boston, MA, April, 1999.
`
`"Current quality of diabetes care in the U. S." American Diabetes Association National Meeting,
`San Antonio, TX, June, 2000.
`
`"Variations in diabetes prevalence, complications and care." Emerging Issues in Health
`Disparities, Symposium sponsored by the Southern California Region of the ACP-ASIM, Los
`Angeles, CA, February, 2001.
`
`"Insulin resistance and type 2 diabetes: when the body does not respond effectively to insulin."
`Advances in Diabetes, Symposium sponsored by GlaxoSmithKline International, Beijing,
`Shanghai, Gangzhou, & Hong Kong, China, March, 2001.
`
`"Hyperglycemia: implications for screening." American Diabetes Association National Meeting,
`Philadelphia, PA, June, 2001.
`
`"Current treatment options for diabetes mellitus." Diabetes Mellitus - Current Trends of
`Treatment, Symposium sponsored by U.S. Botanicals and Botanical Indian Laboratories, Dehli,
`India, July, 2001.
`
`"The relationship between glycemic control and CVD." Regional Postgraduate Course sponsored
`by the American Diabetes Association (National), Los Angeles, CA, July, 2001.
`
`"Is there benefit to treating insulin resistance?" Lecture to select group of endocrinologists and
`cardiologists sponsored by GlaxoSmithKline, Bangkok, Thailand, November, 2002.
`
`- 15 -
`
`Mylan EX 1007, Page 15
`
`

`
`"Participation of insulin resistance in type 2 DM and cardiovascular disease." 14th Annual
`Meeting of The Endocrine Society of Thailand, Bangkok, Thailand, November, 2002.
`
`“The effective use of nurse case management to improve diabetes process and outcome
`measures.” California Cooperative Healthcare Reporting Initiative: CQI Project, Los Angeles,
`CA, April, 2004.
`
`“Successful diabetes counseling and management with indigent patients.” The Diabetes
`Management Colloquium, Sponsored by the Department of Health Policy, Jefferson Medical
`College, Philadelphia, PA, June 2005.
`
`“Effective diabetes disease management in a poor and poorly educated minority population.”
`Understanding and Reducing Disparities in Diabetes Care for Mexicans and Mexican Americans,
`Symposium sponsored by University of California, Irvine Center for Health Policy Research.
`January, 2006.
`
`“Insulin as initial treatment for type 2 diabetes? American Diabetes Association Postgraduate
`Course, San Francisco, CA, February, 2006.
`
`“Effective nurse-directed diabetes care in a minority population.” Southern Regional Conference
`on Diabetes Mellitus, Sponsored by the American Diabetes Association, Marcos Island, FL, May,
`2006.
`
`“How do we recognize diabetes? OGTT vs FBG for the diagnosis of diabetes mellitus and pre-
`diabetes.” Southern Regional Conference on Diabetes Mellitus, Sponsored by the American
`Diabetes Association, Marcos Island, FL, May, 2006.
`
`“Insulin as the initial treatment of type 2 diabetes: no way to go.” American Diabetes Association
`National Meeting, Washington, DC, June, 2006.
`
`“Seeking diabetes control: the use and abuse of SMBG.” Medicare Coverage Advisory
`Committee on Glucose Monitoring, Baltimore, MD, August, 2006.
`
`“The role of incretins and amylin in the pathogenesis of type 2 diabetes and the implication for
`replacement.” New Advances in the Management of Type 2 Diabetes, Symposium sponsored by
`the American Association of Clinical Endocrinologists, Long Beach, CA, September, 2006.
`
`“Diabetes mellitus: what it is and what can be done about it.” National Library of Medicine High
`School Student Lecture Series, Los Angeles, CA, February, 2007.
`
`“Improving diabetes care using nurses to make treatment decisions.” Endocrine Grand Rounds,
`Emory University, Atlanta, GA, March, 2007.
`
`“What’s new in diabetes: from top down to bottom(s) up.” Diabetic Foot Global Conference,
`Sponsored by the Providence Health System, Hollywood, California, March, 2007.
`
`“Can treating insulin resistance (independent of glycemia) be beneficial?” Endocrine Grand
`Rounds, Baylor Hospital, Houston, TX, April, 2007.
`
`- 16 -
`
`Mylan EX 1007, Page 16
`
`

`
`Visiting Professor at The University of Texas Medical School at Houston, “Incretins: a new
`treatment for type 2 diabetes,” Grand Rounds, Houston TX, April, 2007.
`
`“The definition and treatment of pre-diabetes.” Global Diabetes Expert Forum, Sponsored by
`Merck Pharmaceuticals, Inc, Washington, DC, May, 2007.
`
`“Nurse- and pharmacist-directed diabetes care.” American Diabetes Association National
`Meeting, Chicago, IL, June, 2007.
`
`“Does the treatment of diabetes benefit vascular disease?” Diabetic Foot Global Conference,
`Sponsored by the Providence Health System, Hollywood, California, March, 2008.
`
`“Reducing health disparities with nurse-directed diabetes care: carve out vs. carve in models.”
`2nd Annual Health Disparities Conference, Improving Medical Effectiveness and Health
`Outcomes to Eliminate Health Disparities Through Multidisciplinary Collaborations, Sponsored
`by Xavier University of Louisiana, New Orleans, LA, April, 2008.
`
`“Effect of nurse-directed diabetes care in minority patients in a primary care setting.” 2008 CDC
`Diabetes Translational Conference, Orlando, FL, May, 2008.
`
`“There is no benefit to the early use of insulin to control hyperglycemia.” American Diabetes
`Association National Meeting, San Francisco, CA, June, 2008.
`
`“Effect of SMBG on glycemia in non-insulin-requiring diabetic patients: a randomized, blinded,
`clinical trial.” International Diabetes Federation Global SMBG Workshop, Amsterdam,
`Netherlands, October, 2008.
`
`“The cost/benefit of self monitoring of blood glucose in non-insulin-requiring diabetic patients.”
`International Diabetes Federation Global SMBG Workshop, Amsterdam, Netherlands, October,
`2008.
`
`“New American Diabetes Association recommendations for screening and diagnosing diabetes
`mellitus.” Latest Advances in Chronic Disease: Cardiac, Diabetes & Thyroid Diseases,
`Symposium sponsored by the American Association of Clinical Chemists, Newport Beach, CA,
`May, 2009.
`
`“Achieving glycemic control in the severely insulin-resistant patient.” Severe Insulin Resistance:
`Causes, Challenges and Therapeutic Options, Symposium sponsored by the American
`Association of Clinical Endocrinologists, Houston, TX, May, 2009.
`
`“Recent changes in diabetes care.” Diabetes Update, Symposium sponsored by John Stroger
`Hospital of Cook County & Rush University Medical Center, Chicago, IL, November, 2009.
`
`Type 1 diabetes: screening, diagnosis and management.” Advanced Clinical Management of
`Diabetes & Its Complications, Symposium sponsored by the American Diabetes Association, Los
`Angeles, CA, February, 2011.
`
`- 17 -
`
`Mylan EX 1007, Page 17
`
`

`
`“Insulin use for the management of type 2 diabetes.” Advanced Clinical Management of
`Diabetes & Its Complications, Symposium sponsored by the American Diabetes Association, Los
`Angeles, CA, February, 2011.
`
`“Glucose monitoring devices, insulin pumps and diabetes care of the future: what’s on the
`horizon?” Advanced Clinical Management of Diabetes & Its Complications, Symposium
`sponsored by the American Diabetes Association, Los Angeles, CA, February, 2011.
`
`“Can we determine cut-points for the diagnosis of diabetes?” American Diabetes Association
`National Meeting, San D